FY2026 Earnings Estimate for TVTX Issued By Leerink Partnrs

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at Leerink Partnrs raised their FY2026 earnings estimates for Travere Therapeutics in a research note issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of $0.52 for the year, up from their prior forecast of $0.51. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.01. The firm had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The company’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same quarter last year, the business posted ($1.17) EPS.

Other equities analysts have also recently issued reports about the stock. Bank of America raised their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Guggenheim lifted their price target on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. HC Wainwright increased their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Wedbush lifted their target price on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research report on Wednesday, October 9th. Finally, Leerink Partners reissued an “outperform” rating and set a $20.00 price target on shares of Travere Therapeutics in a research report on Tuesday, October 8th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.00.

Travere Therapeutics Trading Down 0.5 %

Shares of Travere Therapeutics stock opened at $18.37 on Tuesday. The business’s 50 day simple moving average is $18.20 and its 200 day simple moving average is $14.63. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $20.33.

Institutional Trading of Travere Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Creative Planning raised its stake in Travere Therapeutics by 4.3% in the 3rd quarter. Creative Planning now owns 23,938 shares of the company’s stock worth $335,000 after purchasing an additional 995 shares in the last quarter. Forefront Analytics LLC increased its holdings in shares of Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after purchasing an additional 1,237 shares during the period. CWM LLC raised its position in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares in the last quarter. Diversified Trust Co boosted its stake in shares of Travere Therapeutics by 27.5% in the fourth quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock valued at $256,000 after buying an additional 3,169 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Travere Therapeutics by 20.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company’s stock worth $279,000 after buying an additional 3,458 shares in the last quarter.

Insider Activity

In other Travere Therapeutics news, insider Jula Inrig sold 2,066 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total transaction of $39,460.60. Following the completion of the sale, the insider now directly owns 59,883 shares in the company, valued at $1,143,765.30. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Sandra Calvin sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. This represents a 21.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,596 shares of company stock valued at $527,262 over the last three months. Insiders own 4.06% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.